GEARS (Global Evaluation of Antimicrobial Resistance via Surveillance)
Conducted by Venatorx
Countries: Argentina, Australia, Belgium, Brazil, Cameroon, Canada, Chile, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Korea (Republic of), Kuwait, Latvia, Lithuania, Malaysia, Mexico, Morocco, Netherlands, New Zealand, Nigeria, Panama, Philippines, Poland, Portugal, Puerto Rico, Qatar, Romania, Russian Federation, Saudi Arabia, Singapore, Slovenia, South Africa, Spain, Sweden, Switzerland, Taiwan, Province of China, Thailand, Turkey, Ukraine, United Kingdom of Great Britain and Northern Ireland, United States of America, Venezuela (Bolivarian Republic of), Viet Nam
To determine AMR rates in key gram-negative pathogens from global sites
|Protocol Summary||Study organisms were clinical isolates previously collected and frozen at -70°C. Isolates were from documented infections (clinically relevant causative agent), with only one isolate per species per patient allowed. Isolates were from community- and hospital-associated infection sources, distributed globally with a focus on the United States and Europe. Patient locations included: General Medicine; Medical ICU; Surgery General; Surgery ICU; Emergency Room; Pediatric ICU; General ICU; and Pediatric General. Isolates were sourced from: respiratory tract infections, urinary tract infections, bloodstream infections, intraabdominal infections, and skin/soft tissue infections. Organisms included Enterobacterales, Pseudomonas aeruginosa, Stenotrophomonas maltophilia and methicillin-susceptible Staphylococcus aureus. The identities of all isolates were confirmed using MALDI-TOF mass spectrometry. Broth microdilution MICs were determined using the ISO 20776-1:2019/CLSI M07 11th Ed. reference method. Quality control (QC) testing was performed each day of testing (CLSI M100).
Inclusions: human infection (clinically relevant causative agent), one isolate per infection episode; Exclusions: screening/carriage isolates, multiple isolates per infection episode.
|Isolates collection method||Clinically relevant causative agent only; one isolate per infection episode.|
|Types of surveillance||Prevalence-based|
|Number of Isolates||24,782|
|Contains pediatric data?||Yes|
|Contains genotype data?||No|
|Date Last Updated||Feb-2023|
|Expected frequency of updates to the dataset||To be determined|
|Publications||Link to (surveillance) posters on Venatorx corporate website provided here: www.venatorx.com